On the absence of interchangeability of botulinum toxin type A drugs
In the Russian Federation, as well as in many countries of the world, several botulinum toxin type A (BTA) drugs are licensed for use as injections; these are biological medicinal products derived from Clostridium botulinum. It is highly important to choose the right drug from the available list or...
Main Authors: | A. R. Artemenko, A. L. Kurenkov, K. V. Belomestova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2015-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/181 |
Similar Items
-
Pharmacoeconomic analysis of Xeomine® for treatment patients with focal dystonia
by: S. K. Zyryanov, et al.
Published: (2018-05-01) -
Botulinum Toxin : Formulation, Concentration and Treatment
by: Rystedt, Alma
Published: (2012) -
Pharmacoeconomic analysis of the use of botulinum toxin in the treatment of poststroke spasticity
by: A. S. Kolbin, et al.
Published: (2018-05-01) -
Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products
by: Jack Xie, et al.
Published: (2010-08-01) -
Neurotoxic denervation of the left atrium for atrial fibrillation treatment and prevention: an experimental animal study
by: А. Г. Стрельников, et al.
Published: (2015-10-01)